InMed Pharmaceuticals Inc. (MWG0.F)
| Previous Close | 0.2555 |
| Open | 0.2485 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's Range | 0.2485 - 0.2485 |
| 52 Week Range | 0.0838 - 0.7900 |
| Volume | |
| Avg. Volume | 1,483 |
| Market Cap | 3.67M |
| Beta (5Y Monthly) | 0.74 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9300 |
| Earnings Date | Nov 12, 2024 - Nov 18, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NewsfileInMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease
Vancouver, British Columbia--(Newsfile Corp. - October 24, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced it will be participating in the upcoming Fierce Biotech webinar "Alzheimer's Outlook - Neuroinflammation, the Next Step," on November 12th, 2024. InMed's Senior Vice President of Preclinical Research
NewsfileInMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board
Vancouver, British Columbia--(Newsfile Corp. - October 22, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the appointment of Dr. Barry Greenberg to its Scientific Advisory Board. Dr. Greenberg is the Director of the Alzheimer's Disease Translational Center and an Associate Professor in the Department of N
